



Institute for  
Interdisciplinary  
Innovation in healthcare

RESEARCH  
EDUCATION  
INNOVATION

COLLABORATION  
ACROSS  
BORDERS



# TABLE OF CONTENTS

- ▶ **THE I<sup>3</sup>h INSTITUTE** **4**
  - MISSION and VISION ..... 4
  - RESEARCH ..... 4
  - EDUCATION ..... 5
  - WHO WE ARE ..... 6
  - BOARD of TRUSTEES ..... 10
  - SCIENTIFIC COLLABORATORS ..... 11
  - PUBLICATIONS ..... 12
  
- ▶ **INTERDISCIPLINARY PROGRAM in HEALTHCARE INNOVATION** **14**
  - LECTURES ..... 14
  - WORKSHOPS ..... 14
  - CASE STUDIES ..... 15
  - FACULTY ..... 16
  
- ▶ **WHAT'S NEXT ?** **26**



# The I<sup>3</sup>h INSTITUTE

## MISSION and VISION

Our overarching objective is to move patient-centered healthcare forward through bridging competencies and expertise from various disciplines and fostering multi-stakeholder collaboration.

As an academic institute, we aim to educate the next generation of healthcare professionals and develop new scientific knowledge on Health as a Common Good.

## RESEARCH

Our aim is to reflect upon and develop solutions addressing the multiple challenges in the healthcare sector.

We follow a system approach to mobilise collective intelligence and incentivise collaborative innovation.

Key areas of interest :

- Vaccine hesitancy
- Patient access to healthcare innovation
- Opioid crisis
- Physician-industry dialogue



## EDUCATION

Benefiting from the philanthropic support of the Baillet Latour Fund, the I<sup>3</sup>h Interdisciplinary Program in Healthcare Innovation is attended by master and PhD students as well as post-doctoral researchers from several Belgian universities :



In 2020, we welcome over 140 students from diverse backgrounds :

- Medicine
- Biomedical and Pharmaceutical sciences
- Public Health
- Economics and Management
- Law
- Bioengineering

Through lectures, workshops and online learning, participants gain competencies to address scientific, business, management and social issues in the healthcare sector.

# WHO WE ARE

## Michel GOLDMAN | Founder & Co-Director



Michel Goldman, M.D., Ph.D., is Professor of Immunology and the Founder of the I<sup>3</sup>h Institute at the ULB. He was the first Executive Director of the Innovative Medicines Initiative (IMI) from 2009 to 2014. Previously, he also served as the Head of the Department of Immunology at the Erasme Hospital and was the first Director of the Institute for Medical Immunology of the ULB. In 1992 he received the Medical Prize Lucien Steinberg and in 2000 the Quinquennial Prize of the Belgian National Fund for Scientific Research for Clinical Sciences. He held the Francqui Chair at the University of Namur in 1999, at the University of Liège in 2003, and the Spinoza Chair at the University of Amsterdam in 2001. Michel Goldman's scientific achievements resulted in an ISI Highly Cited Scientist nomination in 2006. In 2007, Michel Goldman was awarded the degree of Doctor Honoris Causa of the University of Lille.

## Mathias DEWATRIPONT | Co-Director



Mathias Dewatripont holds a Ph.D. in Economics from Harvard University (1986). His general research area is the theory of incentives and organizations. Since 1990, he has been Professor of Economics at the ULB. He is affiliated with ECARES and Solvay Brussels School of Economics and Management, where he previously held positions of Chairman and then Dean (2009 - 2011). He was Executive Director of the National Bank of Belgium between 2011 and 2017 (and its Vice-Governor between June 2014 and March 2015). Between 1998 and 2011, he was part-time Visiting Professor at MIT and Research Director of CEPR. Laureate of the 1998 Francqui Prize and of the 2003 Yrjö Jahnsson Prize for Economics, he was a founding member of the Scientific Council of the European Research Council (2007-2012). He is a member of the Académie Royale De Belgique and Foreign Honorary Member of the American Academy of Arts and Science. In 2019, he was awarded the degree of Doctor Honoris Causa of Universiteit Antwerpen.

## Hilde STEVENS | Baillet Latour Chair in Translational Medicine



Hilde Stevens, Ph.D., is Associate Professor at the ULB and Guest Professor at KU Leuven. Hilde focuses her research on collaborative innovation models, intellectual property, mechanisms governing access to medicines for poverty-related and neglected (tropical) diseases as well as governance and the performance of public-private partnerships (PPPs) and their added value in the acceleration of innovative therapies development. Hilde is a Founding Member of EUPATI.be, the Belgian Patient Platform, where she was Treasurer, Academic Coordinator and Vice-Chair from 2016 to 2019. She holds a master's degree in Biomedical Sciences (Ghent University), a master's degree in General Management (Vlerick Business School), a master's degree in Intellectual Property Law (HUB-KU Brussel) and a Ph.D. in Biomedical Sciences from KU Leuven.

## Micael CASTANHEIRA | Lead Investigator



Micael Castanheira is Research Director at the Belgian National Science Foundation. He obtained his Ph.D. in Economics from the ULB. He was a post-doctoral fellow at Bocconi University and a visiting fellow at NYU. His research focuses mainly on political economics and economic policy, one application of the latter being competition in the pharmaceutical market. He also worked on economic reforms (tax, pensions, institution building). Previously, he acted as an economic expert for a multinational enterprise, for the OECD, and for the World Bank. He sits on the scientific board of the National Bank of Belgium and of the Belgian Price Observatory.

## Sofia AMARAL-GARCIA | Post-doctoral Fellow



Sofia Amaral-Garcia obtained her Ph.D. from the European Doctorate in Law & Economics (University of Bologna and Erasmus University of Rotterdam). Previously, she held research positions at ETH Zurich, New York University, DIW Berlin and Hasselt University. She is an external affiliate of the Health Econometrics and Data Group (York University) and an affiliate of KU Leuven. Sofia's research focuses on empirical health economics and law & economics. More specifically, part of her research assesses how incentives might impact physicians' behaviour. For instance, how malpractice pressure might impact types of treatments provided by physicians, or whether interactions between physicians and medical device industry might affect treatments. Another line of research assesses how technologies such as the internet might change the relationship between health care providers and patients. Currently, Sofia is also working on projects related to rare diseases.

## Ilaria NATALI | Ph.D. Student

Ilaria Natali holds a master's degree in Economic Sciences (University of Florence) and a research master in Economics (ULB). She is a Ph.D. student at ECARES and I<sup>3</sup>h. Her thesis deals with the Regulation in the Pharmaceutical Industry.

## Marie NEUNEZ | Ph.D. Student

Marie Neunez holds a master's degree in Bioengineering (UCLouvain) and a postgraduate degree in Management (ICHEC Business Management School). Currently she is studying Medicine at the ULB. At I<sup>3</sup>h, she is a Research Fellow working on the quality of online health information accessible to the lay public, with a focus on vaccines and probiotics.

## Anna WOZNIAK | External Relations and Events Manager

Anna Wozniak holds a master's degree in Administration in International Organisations (University of Wroclaw, Poland) and executive master's degree in Digital Marketing and Communication (Solvay Business School of Economics and Management, ULB). At I³h, she is responsible for external communication with stakeholders and organisation of major events such as international conferences, symposiums and reading seminars.

## Caroline VAN SWIETEN | Project Coordinator

Caroline Van Swieten holds a master's degree in International Management with a specialization in Economics of Developing Countries from ICHEC Brussels Management School. She started her career in Microfinance and Banking in Africa and Belgium. Most recently, she worked as a project and account manager in a communication agency. Then she gained experience in European affairs and events management as Partnership Manager for the European Business Summit.

# BOARD of TRUSTEES

## CHAIRMAN

- **Yvon ENGLERT**  
Rector of the Université libre de Bruxelles

## MEMBERS

- **Kristin BARTIK**  
Vice-Rector of the Université libre de Bruxelles
- **Jacques BROTCHE**  
Former President of the Belgian Senate
- **Philippe BUSQUIN**  
Minister of State, Belgium
- **Jean-François CATS**  
President of the Board of Directors of Caisse d'investissement de Wallonie
- **Edouard CROUFER**  
Chairman of the Board of the Croix-Rouge de Belgique (French Community)
- **Xavier DECUYPER**  
Head of the Federal Agency for Medicines and Health Products, Belgium
- **Yvan DE LAUNOIT**  
President of the North-West Canceropole, France
- **Françoise MEUNIER**  
Director of Special Projects at European Organisation for Research and Treatment of Cancer
- **Joanne RASSCHAERT**  
Dean of the Faculty of Medicine at the Université libre de Bruxelles
- **Fernand SAUER**  
Founder of the European Medicines Agency
- **Bruno VAN LIERDE**  
Chairman of the Board of the International Chamber of Commerce, Belgium
- **Philip VERGAUWEN**  
Dean of the Solvay Brussels School of Economics and Management, ULB
- **Reinhilde VEUGELERS**  
Full Professor at the Faculty of Economics and Business, KU Leuven

# SCIENTIFIC COLLABORATORS

- **Gani ALDASHEV**  
Professor of Economics, Solvay Brussels School of Economics & Management, ULB
- **Giovanni BRIGANTI**  
Physician-scientist in Psychiatry (ULB); Lecturer in Physiology (ESS, Lausanne)
- **Nicolas DECONINCK**  
Medical Director, University Children's Hospital Queen Fabiola, Brussels, ULB
- **Alain FISCHER**  
Chair in Experimental Medicine, Collège de France, Paris
- **Pietro GHEZZI**  
Phillips Chair in Experimental Medicine, Brighton and Sussex Medical School
- **Victor GINSBURGH**  
Emeritus Professor, ECARES, Solvay Brussels School of Economics & Management, ULB
- **Michel HANSET**  
Professor of Pharmacotherapy, Faculty of Medicine, ULB
- **Isabelle HUYS**  
Professor at Department of Pharmaceutical Sciences, KULeuven
- **Mariana IGOILLO-ESTEVE**  
Senior Investigator, Faculty of Medicine, ULB Center for Diabetes Research
- **Olivier KLEIN**  
Professor of Social Psychology, Faculty of Psychology and Education, ULB
- **Patrick LEGROS**  
Professor of Economics, Solvay Brussels School of Economics & Management, ULB
- **Roland POCHE**  
Secretary General, Belgian Brain Council
- **Georges SIOTIS**  
Associate Professor of Economics, Universidad Carlos III de Madrid
- **Pierre SMEESTERS**  
Head, Department of Pediatrics at the University Children's Hospital Queen Fabiola
- **Jean TIROLE**  
Chairman, Institute for Advanced Study in Toulouse
- **Bruno VAN POTTELSBERGHE**  
Professor of Economics, Solvay Brussels School of Economics & Management, ULB
- **Philip VERGAUWEN**  
Dean, Solvay Brussels School of Economics & Management, ULB
- **Philip VERWIMP**  
Professor of Economics, Solvay Brussels School of Economics & Management, ULB

# SELECTED PUBLICATIONS

- Goldman M. Education in medicine: Moving the boundaries to foster interdisciplinarity. **Frontiers in Medicine** 2016, 3:15 doi:10.3389/fmed.2016.00015.
- Murray, F., P. Aghion, M. Dewatripont, J. Kolev and S. Stern. Of Mice and Academics: Examining the Effect of Openness on Innovation. **American Economic Journal: Economic Policy** 2016.
- Stevens H, Van Overwalle G, Van Looy B, Huys I. IP strategies in early-phase research Public-Private Partnerships. **Nature Biotechnology** 2016, 34(5), 504-10.
- Stevens H, Debackere K, Goldman M, Mahoney RT, Stevens P, Huys I. Vaccines: Accelerating Innovation and Access. **Global Challenges Report** 2017, WIPO Geneva.
- Stevens H and Huys I. Innovative Approaches to Increase Access to Medicines in Developing Countries. **Frontiers in Medicine** 2017, 4:218 doi: 10.3389/fmed.2017.00218
- Arif N, Al-Jefri N, Bizzi IH, Perano GB, Goldman M, Haq Q-I, Chua KL, Mengozzi M, Neunez M, Smith H, Ghezzi P. Fake news or weak science? Visibility and characterization of antivaccine webpages. **Frontiers in Immunology** 2018, 9:1215 doi:10.3389/fimmu.2018.01215.
- Dewatripont M, Goldman M. Free drug samples and the opioid crisis. **New England Journal of Medicine** 2018, 379: 793-794 (letter).
- Stevens H, Huys I. The role of Intellectual Property in Early-Phase Research Public-Private Partnerships in the Biomedical Sector. The Cambridge Handbook of Public-Private Partnerships, Intellectual Property Governance, and Sustainable Development. **Cambridge University Press** 2018
- Janssens R, van Overbeeke E, Verswijvel L, Meeusen L, Coenegrachts C, Pauwels K, Dooms M, Stevens H, Simoens S and Huys I. Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice. **Frontiers in Medicine** 2018, 5:285 doi: 10.3389/fmed.2018.00285.
- Dewatripont M, Goldman M. How to help deflate Americas' opioid bubble? **Project Syndicate** 2019.
- Samaras K, Stahel HT, Goldman M, Le Coultre J, Holly JMP. Editorial: Will obesity become the new normal? What should we do? **Frontiers in Endocrinology** 2019, doi:10.3389/fendo.2019.00250.
- Neunez M, Goldman M, Goldman S, Lambert PH. Vaccines, shots that protect you. **Frontiers for Young Minds** 2019, doi:10.3389/frym.2019.00031.



- Fischer A, Dewatripont M, Goldman M. Benefit Corporation: a path to affordable gene therapies? **Nature Medicine** 2019, 25: 1813-1814.
- Goldman M. EU should take a lead in enforcing the corporate social responsibility of gene therapy manufacturers. **Science Business** 2019, N° 635.
- Bolliger L, Stevens H. From opioid pain management to opioid crisis in the USA: How can Public-Private Partnerships help? **Frontiers in Medicine** 2019, 6:106 doi:10.3389/fmed.2019.00106.
- Castanheira M, Ornaghi C, Siotis G. The unexpected consequences of generic entry. **Journal of Health Economics** 2019, 68:10224.
- Goldman M. Mobilizing young people against anti-vaxxers. **Project Syndicate**, 2019.
- Janssens R, Russo S, van Overbeeke E, Stevens H, *et al.* Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA. **Patient** 2019, doi.org/10.1007/s40271-019-00367-w.
- Neunez M, Ghezzi P, Goldman M. Online information on probiotics: Does it match scientific evidence? **Frontiers in Medicine** 2019, doi:10.3389/fmed.2019.00296.
- Dewatripont J, Tirole J. Incentives and ethics: How markets and organizations shape our moral behavior. **TSE working paper** 2019.
- Janssens R, Huys I, van Overbeeke E, Whichello C, Harding S, Kübler J, Juhaeri J, Ciaglia A, Simoens S, Stevens H, *et al.* Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review. **BMC medical informatics and decision making** 2019, 19(1):189. doi: 10.1186/s12911-019-0875-z.
- Amaral-Garcia, S. Medical Malpractice Appeals in a Civil Law System: Do Administrative and Civil Courts Award Non-Economic Damages Differently? **Law & Society Review** 2019, doi:10.1111/lasr.12398.
- Amaral-Garcia S., M. Nardotto, C. Propper and T Valetti. Mums Go Online: Is the Internet Changing the Demand for Healthcare? **CEPR** 2019, DP 13625
- Natali I, Dewatripont M, Ginsburgh V, Goldman M, Legros P, Natali I. Prescription opioid retail sales and socioeconomic conditions in France. **Ecares working paper** 2020-01.
- Grine L, Janssens R, van Overbeeke E, Derijcke D, Silva M, Delys B, Dusart I, Aertsen V, Mertens de Wilmars M, Robaczewska J, Stevens H. Improving Patient Involvement in the Lifecycle of Medicines: Insights from the EUPATI BE Survey. **Frontiers in Medicine** 2020, doi: 10.3389/fmed.2020.00036.



# INTERDISCIPLINARY PROGRAM in HEALTHCARE INNOVATION

## LECTURES

I

### The FUTURE of HEALTHCARE

- Research and development of innovative medicines
- The evolving mission of regulatory agencies
- Prevention as cornerstone of health systems
- Cell-based therapies: today and tomorrow

II

### REGULATION and INTELLECTUAL PROPERTY

- The economics of the common good applied to health
- Raison d'être and management of intellectual property rights
- Challenges related to Advanced Therapy Medicinal Products

III

### INNOVATION PROCESSES and TOOLS

- Basics of industrial organization
- Open innovation and public-private partnerships
- Young entrepreneurs as drivers of innovation
- Data science and artificial intelligence in medicine

IV

### ADVANCING CLINICAL CARE and PREVENTION

- From first-in human trials to post-marketing surveillance
- Patient centricity in clinical trials
- Precision medicine
- Novel trial designs

V

### From SCIENCE to BUSINESS

- Career opportunities: lessons from healthcare leaders

VI

### The BIG CHALLENGES

## WORKSHOPS

- Negotiating Intellectual Property agreements
- Becoming an entrepreneur in the healthcare space
- Special master class with Heidi Larson and Peter Piot

## CASE STUDIES

- How to tackle the anti-microbial resistance crisis?
- How to improve access to essential medicines in low-income countries?
- How to promote health literacy in the internet era?
- How to leverage the climate change movement for health improvement?
- How to make Europe the leading region in improving cancer outcomes?
- How to accelerate translation of gene therapies in standard of care?
- How to incentivize the development of new therapies for Alzheimer's dementia?
- Lessons from the opioid crisis in USA to prevent its extension in Europe
- Which actions to improve HPV vaccine coverage?
- Which actions to prevent coronavirus outbreaks?
- How to optimize technology transfer from academia to the private sector?
- Which recommendations to leverage artificial intelligence and big data in healthcare?
- Which recommendations for the development of medical devices as innovative therapies?

# FACULTY

## Lieven ANNEMANS



Lieven Annemans is Senior Professor of Health Economics at the Faculty of Medicine at Ghent University. He is former President of ISPOR (International Society of PharmacoEconomics and Outcomes Research) and was previously advisor to the Belgian Minister of Health, and Chairman of the Flemish health council. He received twice the Francqui Chair, a Belgian award for academic excellence. He published approximately 300 papers and four books on health economics, among which the newest is titled "Health economics for non-economists" (Pelckmans Pro, 2018).

## Robert BAROUKI



Robert Barouki is Professor of Biochemistry at the University of Paris and Head of Inserm unit 'Toxicology Pharmacology and Cellular Signaling'. He also heads the clinical metabolomics and proteomic biochemistry lab at the Necker-Enfants Malades Hospital. Robert's research is focused on the impact of environmental contaminants on human health. He is also involved in the networking of French and European research in the field of environment and health, as well as in communicating scientific data to a large audience.

## Tamás BERECZKY



Tamás Bereczky works with the European Patients' Academy for Therapeutic Innovation EUPATI, while also supporting, as a member, the work of the European AIDS Treatment Group. HIV positive since 2003, he served as a member of the board of directors of the EATG for almost 4 years, and also as the co-chair of the European Commission's Civil Society Forum on HIV/AIDS between 2013 and 2015. Tamás holds a Ph.D. based on research into the significance and perspectives of patient organizations in Europe.

## Cédric BLANPAIN



Cédric Blanpain is Full Professor, WELBIO investigator and Director of the laboratory of stem cells and cancer at the ULB. His research group uses lineage-tracing approaches to study the role of SCs during development, homeostasis and cancer. Cédric Blanpain received several prestigious awards including the Liliane Bettencourt award in 2012 and Joseph Maisin Award in 2015. He is a member of the EMBO, the Belgian Royal Academy of Medicine, and the Academia Europaea.

## Giovanni BRIGANTI



Giovanni Briganti is a Medical Doctor specializing in psychiatry and neuroscience. He is a researcher at the Unit of Epidemiology, Biostatistics and Clinical Research at the ULB. His research focuses on computational models of mental disorders with the use of artificial intelligence (AI). He is Lecturer on Physiology at École Supérieure de la Santé in Lausanne, invited Lecturer on AI & Health at the University of Mons, and Associate Lecturer of AI in Medicine for the Medical Informatics course at the ULB.

## Anne DANNIAU



Anne Danniau is heading a Group of Project Lead Statisticians at UCB Pharma, where she contributes to the development of new solutions for patients with unmet needs. Anne has worked in the pharma industry since 1996 and she holds a master's degree in Statistics from Harvard University. She focuses on defining, applying and interpreting the most powerful clinical study designs and statistical tests, while holding dialogue with the Regulatory Authorities that are in charge of approving and pricing new drugs and devices all over the world.

## Nathalie DELZENNE



Nathalie Delzenne is Full Professor at UCLouvain. She is President of the Louvain Drug Research Institute and leads the Research Group in Metabolism and Nutrition. Following a Ph.D. in Pharmaceutical Sciences and a post-doctoral certificate in Nutrition at the University of Lausanne, Nathalie has pioneered the discovery of nutrients (prebiotics) targeting the gut microbiota to control nutritional disorders. She has published more than 300 papers (Highly Cited Researcher 2019) that propose innovative therapeutic approaches by establishing the link between the bacterial ecosystem and key functions

## Jean-Pol DETIFFE



Jean-Pol Detiffe is leading Belgian entrepreneur. He graduated as a pharmacist from the ULB and obtained an MBA from IAG-UCL as well as a post-graduate teaching diploma. In 2012, he founded OncoDNA, a cutting-edge oncology-focused healthcare technology company that provides state-of-the-art solutions to support oncologists in their therapeutical decision-making process, with the final objective of helping patients get the best treatment. OncoDNA employs 55 collaborators in four countries and was awarded several prizes, e.g. Deloitte's 2018 Fast 50 Competition award in Healthcare and Life Science category.

## Lode DEWULF



Lode Dewulf is a passionate leader and global reference for patient engagement in medicines development and use. He left clinical medical practice for a global career in Medical Affairs, spanning over 20 years, in different roles and pharmaceutical companies. He co-founded PlanetMedica, the first healthcare internet portal in Europe, and is currently a board member of a few organizations, including PFMD.org and OpenMedicineInstitute.org. Lode currently works as Chief Patient Officer at Servier, a global pharmaceutical group governed by a foundation.

## Anne-Laure DRENO



Anne-Laure Dreno has been Country President of AstraZeneca Belgium & Luxemburg since June 2019, returning to Belgium after 4 years in the US, where she was Vice-President for Global Marketing of Respiratory Inhaled Products. She has 14 years' experience in the pharmaceutical industry in different commercial roles both locally and internationally. Prior to joining AstraZeneca in 2006, she worked as a consultant in strategy for a broad range of industries from media to consumer goods. She started her career as Project Engineer in the drinking water industry with Suez Lyonnaise des Eaux in Paris.

## Hans-Georg EICHLER



Hans-Georg Eichler is Senior Medical Officer of the European Medicines Agency, where he is responsible for coordinating activities between the Agency's scientific committees and giving advice on scientific and public health issues. From 2015 to 2018, he was the scientific lead for IMI ADAPT SMART consortium on Adaptive Licensing. Prior to joining the EMA, Hans-Georg was at the Medical University of Vienna for 15 years, where he served as Vice-rector for Research and International Relations and Professor and Chair of the Department of Clinical Pharmacology

## Bruno FLAMION



Bruno Flamion is Full Professor of Clinical Pharmacology at the University of Namur and Vice-president, Head Strategic Development at Actelion Pharmaceuticals (Switzerland). He has clinical expertise in internal medicine and served as Research Associate at the National Institutes of Health (USA) and at the Belgian FNRS. He headed the Laboratory of Physiology and Pharmacology at UNamur for 20 years and worked part-time at the European Medicines Agency for 12 years (including 6 as Chair of the Scientific Advice Working Party).

## Emmanuel HANON



Emmanuel Hanon is Senior Vice-president of Vaccines Research and Development at GSK. He leads the research and development organization, covering discovery, early and late development, regulatory and medical affairs activities. Emmanuel joined GSK Vaccines in 2001 taking roles of increasing responsibility in immunology and human cell-mediated immunity before leading the viral vaccines program in R&D. Emmanuel obtained a Ph.D. at University of Liège in the field of immunology and herpes virology and occupied a post-doctorate position in the field of retrovirology at Imperial College.

## Mike HARDMAN



Mike Hardman trained in General Medicine and Clinical Pharmacology in Sheffield, Munich and Oxford. After 10 years of clinical practice and research, he joined the pharmaceutical industry where he worked for 30 years in all stages of clinical drug development. Mike has been involved in multiple international education and training projects and initiatives. Although retired from AZ, he still lectures on several master courses and projects. He is a Fellow of the UK Faculty of Pharmaceutical Medicine.

## Isabelle HUYS



Isabelle Huys is Full Professor at the Faculty of Pharmaceutical Sciences at KU Leuven. She is pharmacist and doctor in pharmaceutical sciences with further specialization in Intellectual Property Rights (IPR) and regulatory sciences. Her research and teaching focuses on IPR, legal and regulatory strategies in the drug life cycle, including biobanking, clinical research pathways and market access, with the aim to promote access to safe, effective, affordable and personalised therapies.



## Yves JONGEN



Yves Jongen is the founder of, and Chief Research Officer at Ion Beam Applications (IBA), a world leader in particle accelerator technology and its applications, particularly in medical imaging, cancer therapy and sterilization. Prior to founding IBA, Yves served for 16 years as manager of the UCL Cyclotron Research Center, a multidisciplinary organization established by UCLouvain. He holds a dozen patents and is the author of approximately 200 publications in the particle accelerator field and their applications.

## Heelung JUNG



HeeJung Jung is an Assistant Professor at Imperial College Business School. She holds a Ph.D. in Management from INSEAD and a B.A. in Communications (Advertising and Public Relations) from Ewha Woman's University. Her research involves the study of how founding conditions shape ventures' performance and future strategies, with a particular focus on founding team dynamics and inequalities. HeeJung teaches Entrepreneurship and Business Plan Competition. She also acts as a jury member in major start-up competitions in UK and in North America, including ShellLiveWire and QEC.

## Dipak KALRA



Dipak Kalra is President of the European Institute for Innovation through Health Data. He has led multiple EC and IMI projects, and ISO standards development, in EHR interoperability standards, data protection, business models and the reuse of EHRs in clinical research. His current projects include the generation of real world evidence in pregnancy, the governance of patient-centric clinical trials, the readiness of hospitals for value-based care, and promoting the value of research to the public.

## Michel KAZATCHKINE



Michel Kazatchkine has over 30 years' experience in the fight against AIDS as a leading physician, researcher, advocate, policy-maker and diplomat. His most recent roles include the positions of Special Advisor to the Joint UN Programme on HIV/AIDS for Eastern Europe and Central Asia, Senior Fellow with the Global Health Centre of the Graduate Institute for International and Development Studies, and a member of the Global Commission on Drug Policy. He holds honorary degrees from Imperial College London, ULB, UCL and University of Geneva.

## Ingrid KLINGMANN



Ingrid Klingmann has over 30 years of experience in senior medical, operational and managerial functions in pharmaceutical industry, CROs and clinical trial sites, with focus on clinical trial design and management, ethical and regulatory aspects. Since January 2003, she has developed her own pharmaceutical development and site management support consulting company. Currently, she also serves as Chairman of the European Forum for Good Clinical Practice and President of PharmaTrain Federation. She is involved in different FP7- and IMI-funded projects, e.g., EUPATI, PARADIGM, Combacte and LENA.

## Anatole KRATTIGER



Anatole Krattiger is founding Partner of Prisma Innovations LLC, that provides advisory, management services and training seminars for the joint development of solutions to problems that extend beyond geographic, cultural and technological frontiers in the areas of global health, climate change, food security, organizational processes, IP management, the sharing economy, and blockchain applications. He teaches at Cornell University as Adjunct Professor, and previously served as a Director at WIPO in Geneva, led ISAAA, and worked at CIMMYT in Mexico.

## Patrick LEGROS



Patrick Legros holds a Ph.D. in Economics from the University of Paris and a Ph.D. in Social Sciences from the California Institute of Technology. He is a Professor of Economics at the ULB and at Northeastern University (on leave in 2020) as well as a fellow of ECARES and of CEPR. He is the Managing Editor of the Journal of Industrial Economics. His research is focused on applied microeconomics, with an emphasis on industrial organization and competition policy.

## Frank LUYTEN



Frank Luyten is Full Professor in the Faculty of Medicine at the KU Leuven and Chairman of the Division of Rheumatology at the University Hospitals Leuven. He also serves as Director of the Skeletal Biology and Engineering Research Center, KU Leuven and as Director of Prometheus, Division of Skeletal Tissue Engineering, Leuven R&D, KU Leuven. He has been recently appointed as Medical and Scientific Director of REGMED-XB, a public-private platform between the Netherlands and Flanders, focusing on the development and industrialization in the field of regenerative medicine.

## Azèle MATHIEU



Azèle Mathieu is currently working as manager of lifetech.brussels, the health cluster of the Brussels Capital Region, supporting each year the development of around 90 innovative projects. In 2016, Azèle set up the first Belgian MedTech start-up acceleration program; the same year, she contributed to the launching of the regional governance platform gathering policy makers, industry & hospitals (ehealth.brussels) for the interoperability of medical data. Azèle holds a Ph.D. in Economics and Management and a Master of Sciences in Management from the Solvay Brussels School.

## Mattias NEYT



Mattias Neyt obtained a Ph.D. in 2006 from Ghent University with a dissertation entitled 'Economic evaluation of medical innovations'. Since 2005, he has been working as Senior Health Economist at the Belgian Health Care Knowledge Centre (KCE), an independent federal agency providing advice to policy makers. He is the founder of ME-TA (Medical Evaluation and Technology Assessment) that conducts systematic reviews and HTAs for foreign non-profit organizations and provides professional training in HTA and economic evaluations.

## Pedro OLIVEIRA



Pedro Oliveira is Professor MSO at Copenhagen Business School, Gulbenkian Chair Professor at Nova School of Business and Economics, and Academic Fellow at Cornell University. He is Founder and President of Patient Innovation, co-founder of PPL-Crowdfunding and member of the Environment and Sustainability Board of EDP. Previously he was Professor at Católica-Lisbon School of Business and Economics, International Faculty Fellow at MIT-Sloan and Advisor to the Portuguese Ministry of Science, Technology and Higher Education. He received his Ph.D. from the University of North Carolina.

## Ellen 't HOEN



Ellen 't Hoen is a lawyer and director of Medicines Law & Policy, a group of legal and policy experts offering advice to international organizations and governments. She is the founder of the Medicines Patent Pool and a researcher at the University Medical Center Groningen. She has published widely and is the author of several books. In 2017 she received the Prix Prescrire for her latest book 'Private Patents and Public Health: Changing intellectual property rules for public health.'

## Dimitrios TZALIS



Dimitrios Tzalis holds a Ph.D. from the University of California. After a postdoctoral training at the Philips University Marburg, Germany, he founded Taros in 1999, and has been active as a serial biotech entrepreneur ever since. As a Project Executive and Head of Chemistry, he led the chemistry activities of the EUR 196 million early drug discovery platform „European Lead Factory“ (ELF). Dimitrios is the author of more than 15 publications and holds 4 patents.

## Pierre VAN DAMME



Pierre Van Damme is Full Professor at the University of Antwerp, Faculty of Medicine and Health Sciences where he chaired the Vaccine & Infectious Disease Institute (VAXINFECTIO) from 2007 until 2018, and now became Vice-dean of the Faculty. VAXINFECTIO is a consortium of four research units he founded in 2007-2008: Laboratory of Medical Microbiology (LMM), Laboratory of Experimental Hematology (LEH), Centre of Health Economic Research and Infectious Disease Modelling (CHERMID), and Centre for the Evaluation of Vaccination (CEV); the latter is headed by Pierre.

## Bruno VAN POTTELSBERGHE



Bruno van Pottelsberghe is Full Professor and holds the Solvay Chair of Innovation at ULB where he teaches economics & management of innovation and intellectual property. His research focuses on patenting systems, patents' evaluation, and science and technology policies. Previously, he served as Chief Economist at the European Patent Office, Dean of the Solvay Brussels School of Economics and Management, and Chairman of the QTEM Master network (Quantitative Techniques for Economics and Management).

#

## WHAT'S NEXT ?

The ULB Faculty of Medicine and the Solvay Brussels School of Economics and Management will join forces to launch a Chair on "**Health, Innovation and Society**" supported by the university.

Furthermore, the I<sup>3</sup>h Institute is raising funds for a new Chair dedicated to "**Corporate Social Responsibility in Healthcare Industries**" addressing key questions in the new healthcare era including:

- How to optimize the organization of healthcare industries?
- How to mobilize collective intelligence and optimize partnerships for developing innovative healthcare medicines and technologies?

**New education activities** will be initiated in partnership with European universities in the framework of ADVANCE, an **Erasmus+ learning project** dedicated to Advance Therapy Medicinal Products.

**Awareness-raising** further expands and will take advantage of our involvement in the Panel Santé created by Sciences Po (Institut d'études politiques de Paris) and CapGemini to provide recommendations to policymakers on key issues in the healthcare sector.

### Further information

Contact person : [Anna Wozniak](mailto:Anna.Wozniak@i3health.eu)  
[info@i3health.eu](mailto:info@i3health.eu)

Phone : +32 (0)2 650 63 55

Website : <http://i3health.eu/>



Institute for  
Interdisciplinary  
Innovation in healthcare





# SUPPORT I<sup>3</sup>h



I<sup>3</sup>h is a non-profit independent institute. Your support is essential for the development and sustainability of our activities.

Donations which are tax-deductible above 40 € can be made by bank transfer :

**IBAN** : BE79 2100 4294 0033  
**BIC** : GEBABEBB  
**Communication** : 5D I3h donation

Thank you !